Today, the majority of cancers are found too late, when the prognosis is often poor and treatment options are limited.1 The earlier that cancer is diagnosed, the greater the chance of successful treatment and survival.2
Routine screening tests are recommended for cancers such as breast, cervical, colorectal and lung, because they have been shown to decrease cancer-specific mortality for the individual cancers that they detect.4
The Galleri test’s performance is supported by rigorous clinical studies with more than 20,000 participants representing diverse populations.3 – 5
The Galleri® test is a multi-cancer early detection test that detects methylation patterns of cell-free DNA (cfDNA) that could indicate the presence of cancer. When a cancer signal is detected, the test predicts the origin of the cancer signal with high accuracy. The Galleri test should be used in addition to guideline-recommended cancer screenings and is recommended for patients at elevated risk for cancer such as those aged 50 or older.
*The Galleri test is intended to detect a cancer signal and predict cancer signal origin to inform diagnostic evaluation.
Cancer cases enrolled in CCGA Study1 were assigned a“cancer type” as defined in the American Joint Committee on Cancer (AJCC) manual (8th edition)2 (For this list of Cancer types detected, some of the names were modified/edited to organize for easy reference). Cancer signals were detected across more than 50 AJCC-cancer types, which supports the potential for the Galleri test to detect a cancer signal over a diverse range of cancers across a wide biologic spectrum.